CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the...
Hence then, the article about clinical research results for kelun biotech s trop2 adc sacituzumab tirumotecan sac tmt published in nature medicine a top international medical journal was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal )
Also on site :
- US Congressman denies existence of Palestinians in interview
- Mumbai rain havoc: Schools and colleges shut on Monday; flights hit, roads flooded
- The CEO who vowed to ‘fire anyone who doesn’t use AI’ admits that the technology can’t replace her executive assistant as the role evolves